Remepy is harnessing the power of our digital world to improve drugs. We combine medicine with tailored software applications, triggering brain mechanisms that positively influence our immune system, increasing drug efficacy and safety. We offer our platform to pharma companies, enabling them to launch patentable software-drug combinations.
Total raised: $15M
Founded date: 2022
Investors 5
| Date | Name | Website |
| - | StageNext ... | stagenext.... |
| - | TechAviv F... | techaviv.c... |
| 29.11.2022 | TechAviv F... | fund.techa... |
| 11.09.2024 | PsyMed Ven... | psymed.ven... |
| 27.01.2023 | Supernode ... | supernode.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.05.2024 | Seed | $15M | - |
Mentions in press and media 8
| Date | Title | Description |
| 10.11.2025 | Mamdani win rattles Israeli business community in New York City | On October 29, Israeli tech entrepreneurs gathered on a lower Manhattan podium to ring the opening bell of the New York Stock Exchange’s trading floor, in a show meant to celebrate the innovations and contributions of Israeli-founded startu... |
| 10.10.2024 | 97212 Ventures: Interview With Founder Eyal Bino About The Israel-Based Venture Firm | 97212 Ventures is a seed fund exclusively focused on investing in top early stage Israeli startups committed to building category defining companies in NYC. Pulse 2.0 interviewed 97212 Ventures founder Eyal Bino to learn more about the firm... |
| 07.05.2024 | Remepy Revolutionizes Drug Development with Hybrid Drugs | Remepy, a groundbreaking startup, is shaking up the pharmaceutical industry with its innovative hybrid drugs. These revolutionary medications combine traditional drugs with digital molecules, creating a potent combination that targets a wid... |
| 07.05.2024 | Remepy: Hybrid Drug Company Secures $15 Million | Remepy, a pioneer in hybrid drugs, announced that it closed a $10 million seed investment round, totaling $15 million when combined with earlier funding. This funding round was led by NFX and was joined by Vine Ventures, PsyMed Ventures, Su... |
| 01.05.2024 | Remepy raises $10 million Seed round to bring first hybrid drug to market | Remepy raises $10 million Seed round to bring first hybrid drug to market The Israeli startup’s new hybrid drugs combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiologi... |
| 01.05.2024 | Remepy Closes $15M Seed Funding | Remepy, a New York-based hybrid drugs developer, closed a $10M seed funding round, which, together with earlier funding, totalled $15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Vent... |
| 14.02.2024 | Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board for hybrid drug endeavor | This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Gol... |
| - | Remepy Healthcare | “Remepy” |